MaxCyte, Inc. Clinical & Commercial Agreement with Kite (5188R)

TIDMMXCT TIDMTTM

RNS Number : 5188R

MaxCyte, Inc.

01 March 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

MaxCyte Announces Multi-Drug Clinical & Commercial Agreement

with Kite, a Gilead Company

Gaithersburg, Maryland - 01 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte's Flow Electroporation(R) Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

"We're excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics," said Doug Doerfler, President & CEO of MaxCyte, Inc.

The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018. Under the terms of the new license agreement, Kite obtains non-exclusive clinical and commercial-use rights to MaxCyte's cell engineering platform to develop CAR-T therapies, and MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.

About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA(TM) therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation(R) Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

For further information, please contact:

 
 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Ron Holtz, Chief Financial Officer        [phone] 
 Nominated Adviser and Broker 
  Panmure Gordon 
  Emma Earl 
  Freddy Crossley 
  Corporate Broking 
  James Stearns                               [phone] 
 Financial PR Adviser 
  Consilium Strategic Communications          [phone] 
  Mary-Jane Elliott                           [e-mail] 
  Chris Welsh 
  Sukaina Virji 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRLFFEFFFITFIA

(END) Dow Jones Newswires

March 01, 2019 02:01 ET (07:01 GMT)